Skip to main content
VERU
NASDAQ Life Sciences

Veru Narrows Q3 Loss, Fully Enrolls Obesity Trial, and Secures Key Patent Allowance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.408
Mkt Cap
$37.397M
52W Low
$2.05
52W High
$7.33
52W Position info
17% above low
Off High info
67% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

VERU sits 17% above its 52-week low of $2.05 on light trading volume (0.1× avg).

Summary

A narrower Q3 loss, full enrollment of 239 patients in the Phase 2b obesity trial, and a key patent allowance all signal positive momentum ahead of the Q1 2027 interim data readout.


Key Events · Earnings and Guidance · VERU

  • Q3 Loss Narrows

    Net loss of $7.0M ($0.30/share) vs. $7.3M ($0.50/share) a year ago; R&D rose to $4.4M, G&A fell to $3.4M.

  • Phase 2b Trial Fully Enrolled

    PLATEAU study enrolled 239 patients, exceeding the 200-patient target; interim analysis on track for Q1 2027, topline data Q4 2027.

  • Key Patent Allowance

    USPTO notice of allowance for enobosarm+semaglutide combination patent, extending U.S. protection to at least October 2044.

  • Cash Runway

    Cash of $23.9M as of June 30, 2026, up from $15.8M at fiscal year-end, providing funding into 2027.


Analysis · VERU · Life Sciences

Fiscal Q3 results show a narrowed net loss of $7.0M ($0.30/share) compared with $7.3M a year ago, while cash of $23.9M extends the runway into 2027. The Phase 2b PLATEAU obesity trial has fully enrolled 239 patients — exceeding the 200-patient target — keeping the interim readout on track for Q1 2027. A USPTO notice of allowance for a key enobosarm+semaglutide patent strengthens IP protection to at least 2044, enhancing the asset's value. Together, these updates reduce near-term clinical risk and reinforce the investment thesis ahead of the pivotal interim analysis.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VERU was trading at $2.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37.4M. The 52-week trading range was $2.05 to $7.33. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VERU - Latest Insights

VERU
Sep 08, 2026, 8:17 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.82
Real-time Price: $2.06 info
Change: -$0.760 (-27%) info
Market Cap: $35.465M info
VERU
Sep 08, 2026, 8:17 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.81
Real-time Price: $2.06 info
Change: -$0.750 (-27%) info
Market Cap: $35.465M info
VERU
Aug 10, 2026, 8:51 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.45
Real-time Price: $2.06 info
Change: -$0.390 (-16%) info
Market Cap: $35.465M info
VERU
Aug 10, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.29
Real-time Price: $2.06 info
Change: -$0.230 (-10%) info
Market Cap: $35.465M info
VERU
Jul 27, 2026, 8:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $2.34
Real-time Price: $2.06 info
Change: -$0.280 (-12%) info
Market Cap: $35.465M info